Sp302

HEPATIC PATHOLOGY FOR THE GI PROVIDER

Date
May 18, 2024


Tracks

Related Products

Thumbnail for Career Planning for APPs (Hep Associations Committee)
Career Planning for APPs (Hep Associations Committee)
ADDICTION TREATMENT AND HARM REDUCTION IN VIRAL HEPATITIS
Thumbnail for PATHOLOGICAL CHARACTERISTICS AND ROLE OF PLASMA CELLS IN REFRACTORY PRIMARY BILIARY CHOLANGITIS: IMPLICATIONS FOR TARGETED THERAPY
PATHOLOGICAL CHARACTERISTICS AND ROLE OF PLASMA CELLS IN REFRACTORY PRIMARY BILIARY CHOLANGITIS: IMPLICATIONS FOR TARGETED THERAPY
BACKGROUND: Approximately 40% of primary biliary cholangitis (PBC) patients exhibit poor response to ursodeoxycholic acid (UDCA) and prognosis, referred to as refractory PBC. There is an urgent need to explore new treatment approaches for this patient population…